The key facts about the US in relation to Coloplast’s Q4 margin and catheter codes are limited to the information provided in the source.
Coloplast’s Q4 margin is reported to be 23%. This is the only specific information about the US provided in the source. The source does not provide any additional details about the US, such as its role in Coloplast’s operations or any specific actions taken by the US.
The source does mention that the US adds catheter codes, but it does not provide any further context or information about this action. It is also stated that this information is available on TradingView, but the source does not provide any additional details about TradingView or its relevance to the US.
Overall, the information provided by the source is limited to Coloplast’s Q4 margin and the US adding catheter codes, with no additional context or details about the US.